Analysts are confident about the athleisure company's upcoming results, but less sure about its long-term prospects.

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Despite a recent third-quarter earnings miss, reporting adjusted EPS of $0.79 versus the expected $0.89 and revenue of $15.31 ...

Morgan Stanley (MS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Compared to the aggregate P/E ratio of the 21.42 in the Capital Markets industry, Morgan Stanley Inc. has a lower P/E ratio ...

Morgan Stanley (MS) closed at $128.68 in the latest trading session, marking a +0.22% move from the prior day. The stock lagged the S&P 500's daily gain of 0.58%. Elsewhere, the Dow saw an upswing of ...

All three major averages closed out May with sizable gains Friday, with the S&P 500 and Nasdaq Composite seeing their best ...

Indian benchmark indices, Sensex and Nifty, traded lower on Tuesday as worries over global trade tensions dampened investor ...

It turns out that the stocks offering the best returns for investors historically experienced incredibly painful max ...

The word on The Street in general, suggests a Strong Buy analyst consensus rating for EQT with a $59.28 average price target, implying a 6.60% upside from current levels. In a report released on May ...

Invest in Eaton Vance Municipal Income Trust for tax-free income, top returns & dividend growth. Click for more on the EVN ...